246 related articles for article (PubMed ID: 33515070)
1. Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial.
Assfalg R; Knoop J; Hoffman KL; Pfirrmann M; Zapardiel-Gonzalo JM; Hofelich A; Eugster A; Weigelt M; Matzke C; Reinhardt J; Fuchs Y; Bunk M; Weiss A; Hippich M; Halfter K; Hauck SM; Hasford J; Petrosino JF; Achenbach P; Bonifacio E; Ziegler AG
Diabetologia; 2021 May; 64(5):1079-1092. PubMed ID: 33515070
[TBL] [Abstract][Full Text] [Related]
2. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial.
Bonifacio E; Ziegler AG; Klingensmith G; Schober E; Bingley PJ; Rottenkolber M; Theil A; Eugster A; Puff R; Peplow C; Buettner F; Lange K; Hasford J; Achenbach P;
JAMA; 2015 Apr; 313(15):1541-9. PubMed ID: 25898052
[TBL] [Abstract][Full Text] [Related]
3. Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol.
Ziegler AG; Achenbach P; Berner R; Casteels K; Danne T; Gündert M; Hasford J; Hoffmann VS; Kordonouri O; Lange K; Elding Larsson H; Lundgren M; Snape MD; Szypowska A; Todd JA; Bonifacio E;
BMJ Open; 2019 Jun; 9(6):e028578. PubMed ID: 31256036
[TBL] [Abstract][Full Text] [Related]
4. Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.
; Krischer JP; Schatz DA; Bundy B; Skyler JS; Greenbaum CJ
JAMA; 2017 Nov; 318(19):1891-1902. PubMed ID: 29164254
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune responses to the beta cell autoantigen, insulin, and the INS VNTR-IDDM2 locus.
Sarugeri E; Dozio N; Belloni C; Meschi F; Pastore MR; Bonifacio E
Clin Exp Immunol; 1998 Dec; 114(3):370-6. PubMed ID: 9844045
[TBL] [Abstract][Full Text] [Related]
6. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.
Näntö-Salonen K; Kupila A; Simell S; Siljander H; Salonsaari T; Hekkala A; Korhonen S; Erkkola R; Sipilä JI; Haavisto L; Siltala M; Tuominen J; Hakalax J; Hyöty H; Ilonen J; Veijola R; Simell T; Knip M; Simell O
Lancet; 2008 Nov; 372(9651):1746-55. PubMed ID: 18814906
[TBL] [Abstract][Full Text] [Related]
7. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
[TBL] [Abstract][Full Text] [Related]
8. A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab.
Mathieu C; Wiedeman A; Cerosaletti K; Long SA; Serti E; Cooney L; Vermeiren J; Caluwaerts S; Van Huynegem K; Steidler L; Blomme S; Rottiers P; Nepom GT; Herold KC;
Diabetologia; 2024 Jan; 67(1):27-41. PubMed ID: 37782353
[TBL] [Abstract][Full Text] [Related]
9. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial.
Füchtenbusch M; Rabl W; Grassl B; Bachmann W; Standl E; Ziegler AG
Diabetologia; 1998 May; 41(5):536-41. PubMed ID: 9628270
[TBL] [Abstract][Full Text] [Related]
10. Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial.
de Groot PF; Nikolic T; Imangaliyev S; Bekkering S; Duinkerken G; Keij FM; Herrema H; Winkelmeijer M; Kroon J; Levin E; Hutten B; Kemper EM; Simsek S; Levels JHM; van Hoorn FA; Bindraban R; Berkvens A; Dallinga-Thie GM; Davids M; Holleman F; Hoekstra JBL; Stroes ESG; Netea M; van Raalte DH; Roep BO; Nieuwdorp M
Diabetologia; 2020 Mar; 63(3):597-610. PubMed ID: 31915895
[TBL] [Abstract][Full Text] [Related]
11. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children.
Ziegler AG; Rewers M; Simell O; Simell T; Lempainen J; Steck A; Winkler C; Ilonen J; Veijola R; Knip M; Bonifacio E; Eisenbarth GS
JAMA; 2013 Jun; 309(23):2473-9. PubMed ID: 23780460
[TBL] [Abstract][Full Text] [Related]
12. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization.
Achenbach P; Barker J; Bonifacio E;
Curr Diab Rep; 2008 Apr; 8(2):87-93. PubMed ID: 18445349
[TBL] [Abstract][Full Text] [Related]
13. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
Keymeulen B; van Maurik A; Inman D; Oliveira J; McLaughlin R; Gittelman RM; Roep BO; Gillard P; Hilbrands R; Gorus F; Mathieu C; Van de Velde U; Wisniacki N; Napolitano A
Diabetologia; 2021 Feb; 64(2):313-324. PubMed ID: 33145642
[TBL] [Abstract][Full Text] [Related]
14. First-phase insulin response in young healthy children at genetic and immunological risk for Type I diabetes.
Keskinen P; Korhonen S; Kupila A; Veijola R; Erkkilä S; Savolainen H; Arvilommi P; Simell T; Ilonen J; Knip M; Simell O
Diabetologia; 2002 Dec; 45(12):1639-48. PubMed ID: 12488953
[TBL] [Abstract][Full Text] [Related]
15. Supplementation with
Ziegler AG; Arnolds S; Kölln A; Achenbach P; Berner R; Bonifacio E; Casteels K; Elding Larsson H; Gündert M; Hasford J; Kordonouri O; Lundgren M; Oltarzewski M; Pekalski ML; Pfirrmann M; Snape MD; Szypowska A; Todd JA;
BMJ Open; 2021 Nov; 11(11):e052449. PubMed ID: 34753762
[TBL] [Abstract][Full Text] [Related]
16. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY).
Barker JM; Barriga KJ; Yu L; Miao D; Erlich HA; Norris JM; Eisenbarth GS; Rewers M;
J Clin Endocrinol Metab; 2004 Aug; 89(8):3896-902. PubMed ID: 15292324
[TBL] [Abstract][Full Text] [Related]
17. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy.
Orban T; Farkas K; Jalahej H; Kis J; Treszl A; Falk B; Reijonen H; Wolfsdorf J; Ricker A; Matthews JB; Tchao N; Sayre P; Bianchine P
J Autoimmun; 2010 Jun; 34(4):408-15. PubMed ID: 19931408
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial.
Elding Larsson H; Lundgren M; Jonsdottir B; Cuthbertson D; Krischer J;
Pediatr Diabetes; 2018 May; 19(3):410-419. PubMed ID: 29171140
[TBL] [Abstract][Full Text] [Related]
19. Clinical and genetic correlates of islet-autoimmune signatures in juvenile-onset type 1 diabetes.
Claessens LA; Wesselius J; van Lummel M; Laban S; Mulder F; Mul D; Nikolic T; Aanstoot HJ; Koeleman BPC; Roep BO
Diabetologia; 2020 Feb; 63(2):351-361. PubMed ID: 31754749
[TBL] [Abstract][Full Text] [Related]
20. Late-onset islet autoimmunity in childhood: the Diabetes Autoimmunity Study in the Young (DAISY).
Frohnert BI; Ide L; Dong F; Barón AE; Steck AK; Norris JM; Rewers MJ
Diabetologia; 2017 Jun; 60(6):998-1006. PubMed ID: 28314946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
